Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC2642 icec0943

Novel selective inhibitor of CDK7

DCC2643 Ici-185282

Potent thromboxane receptor antagonist

106393-80-0
DCC2644 Ici-56780

Antimalarial agent, displaying blood schizonticidal activity against P.berghei

28130-28-1
DCC2645 Iclaprim

Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms

192314-93-5
DCC2646 Icl-ccic-0019

Novel potent and selective inhibitor of choline kinase alpha (CHKA)

936498-64-5
DCC2647 Icl-sirt078

Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line

1060430-64-9
DCC2648 Icpd62

Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines

DCC2649 Icrf-193

DNA topoisomerase II inhibitor

21416-88-6
DCC2650 Ict2700

Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers

DCC2651 Id110460001

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

1110883-26-5
DCC2652 Id110460002

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

1172882-21-1
DCC2653 Id110460003

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

1428367-46-7
DCC2654 idaverine

M1 and M2 Antagonist

100927-13-7
DCC2655 Ide-in-37 Tfa Salt

Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations

DCC2656 Ide-in-63 Tfa Salt

Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations

DCC2657 Idh2 Inhibitor

Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer

DCC2658 Idi-3783

Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor

901031-43-4
DCC2659 Ido1/2 Inhibitor 4t

The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM)

DCC2660 idoxifene

Selective ER modulator (SERM)

116057-75-1
DCC2661 Idr-0081053

Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations

DCC2662 Idr-0099118

Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions

693804-72-7
DCC2663 Idr-1002

Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin

Page 1342 / Total 1557 FirstPrevNextLastGoto